Lercanidipina Cloridrato Pensa

Lercanidipine Hydrochloride, the active ingredient in Lercanidipina Cloridrato Pensa, is a calcium channel blocker presented as an oral tablet for oral use. It is indicated for the treatment of hypertension in adult patients. GNH USA supplies Lercanidipina Cloridrato Pensa as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Lercanidipine Hydrochloride is a calcium channel blocker used in the management of high blood pressure. Hypertension: lowers systolic and diastolic blood pressure, helping to reduce the risk of cardiovascular events.

Lercanidipine may cause a range of adverse reactions, most of which are mild and transient.

Common Side Effects: - Headache: mild to moderate intensity. - Flushing: warmth and redness of the skin. - Peripheral edema: swelling of the ankles or feet. - Dizziness: sensation of light‑headedness. - Tachycardia: increased heart rate. - Fatigue: general feeling of tiredness.

Serious or Rare Side Effects: - Severe hypotension: marked drop in blood pressure requiring medical attention. - Myocardial infarction: rare occurrence of heart attack. - Angioedema: swelling of face, lips, or throat. - Elevated liver enzymes: indication of hepatic stress. - Severe allergic reactions: rash, itching, or anaphylaxis. - Cardiac conduction abnormalities: heart block or arrhythmias.

Patients should be advised of safety considerations before starting therapy. - Blood pressure monitoring: check regularly to ensure therapeutic response. - Hepatic impairment: use with caution in patients with liver disease. - Elderly patients: start at the lowest effective dose and monitor closely. - Concomitant antihypertensives: avoid excessive blood pressure lowering. - Discontinuation: do not stop abruptly without medical guidance. - Store at ambient temperature: keep in the original container, protect from moisture and direct sunlight.

Lercanidipine can interact with several drug classes, requiring attention to avoid adverse outcomes.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may increase plasma levels. - Grapefruit juice: can raise drug concentration and risk of hypotension. - Co‑administration with other potent antihypertensives: may cause excessive blood pressure drop.

Moderate Interactions (Monitor Closely):\n- CYP3A4 inducers (e.g., rifampicin, carbamazepine): may reduce efficacy. - NSAIDs: may blunt antihypertensive effect. - Diuretics: can increase risk of electrolyte imbalance. - Beta‑blockers: may enhance bradycardia. - Lipid‑lowering agents (e.g., statins): monitor for potential increased statin levels.